PacingCure wins the Venture Challenge 2020

Amsterdam UMC spin-off PacingCure is the winner of the Venture Challenge at the online edition of the Dutch Life Science Conference on the 26th of November. PacingCure develops precision gene therapies for common cardiac arrhythmias and cardiomyopathies, aiming to restore the natural pacing of the heart. The company is founded on combined research from the departments of Cardiology and Medical Biology of the AMC.

The PacingCure team, consisting of Geert Boink, Hanno Tan and Osne Kirzner, participated in the summer edition of the Venture Challenge. In this 10-week bootcamp program, life science start-ups work to sharpen and validate their business idea. During the program, the participating start-ups produce a venture plan and pitch their business in front of an expert jury. This year, the jury consisting of Carine van den Brink, Eline Vrijland, Andre van de Sande, Kim Lucassen and Geert-Jan Mulder, agreed that “PacingCure is addressing a high unmet medical need that they can target with their gene-therapy. They have identified a clear first orphan indication to prove their technique. Moreover, they are a very experienced team of clinicians.”

PacingCure is awarded €25.000,- in price money that they will invest in the further growth of their company. The vision of the company is to become a world leader in cardiac gene therapy.
PacingCure is developing therapies that offer superior treatment over established implantable and medicinal therapies to patients suffering from severe morbidity and mortality, and a cure for patients who are currently untreatable. Their in-vivo validated gene therapies are injected directly into a small region of the heart using a simple, minimal-invasive procedure.